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Abstract
Background: Maternal deprivation (MD) during neonatal life can have long-term effects on metabolism and
behavior, with males and females responding differently. We previously reported that MD during 24 h at postnatal
day (PND) 9 blocks the physiological neonatal leptin surge in both sexes. It is known that modifications in neonatal
leptin levels can affect metabolism in adulthood. Thus, we hypothesized that at least some of the long-term
metabolic changes that occur in response to MD are due to the decline in serum leptin during this critical period
of development. Hence, we predicted that treatment with leptin during MD would normalize these metabolic
changes, with this response also differing between the sexes.
Methods: MD was carried-out in Wistar rats for 24 h on PND9. Control and MD rats of both sexes were treated
from PND 9 to 13 with leptin (3 mg/kg/day sc) or vehicle. Weight gain, food intake, glucose tolerance, and pubertal
onset were monitored. Sexual behavior was analyzed in males. Rats were killed at PND90, and serum hormones and
hypothalamic neuropeptides involved in metabolic control and reproduction were measured. Results were analyzed
by three-way analysis of covariance using sex, MD, and leptin treatment as factors and litter as the covariate and
employing repeated measures where appropriate.
Results: In males, MD advanced the external signs of puberty and increased serum insulin and triglyceride levels
and hypothalamic proopiomelanocortin mRNA levels at PND90. Neonatal leptin treatment normalized these
effects. In contrast, MD decreased circulating triglycerides, as well as estradiol levels, in females at PND90 and
these changes were also normalized by neonatal leptin treatment. Neonatal leptin treatment also had long-term
effects in control rats as it advanced the external signs of puberty in control males, but delayed them in females.
Neonatal leptin treatment increased serum insulin and hypothalamic mRNA levels of the leptin receptor and
cocaine- and amphetamine-regulated transcript in control males and increased orexin mRNA levels in controls of
both sexes. Although pubertal onset in males was advanced by either MD or neonatal leptin treatment in males
and delayed by leptin treatment in females, the mRNA levels of hypothalamic neuropeptides and receptors
related to reproduction were not affected by MD or neonatal leptin treatment in either sex at PND90.
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Conclusions: These findings indicate that some of the long-term changes in metabolic and reproductive
parameters induced by MD, such as advanced pubertal onset and increased hypothalamic proopiomelanocortin
(POMC) expression, hyperinsulinemia, and hypertriglyceridemia in adult males and decreased serum triglyceride
and estradiol levels in females, are most likely due to the decrease in leptin levels during the period of MD.
Keywords: Neonatal leptin surge, Sexual dimorphism, Neuropeptides, Hypothalamus, Puberty, Reproduction,
Weight gain
Background
Numerous studies have investigated the long-term im-
pact of early stress in attempt to understand how the en-
vironment during development affects later health and
well-being [1–4]. As hypothalamic development in ro-
dents is not complete until the adolescent period, early
environmental stress could disrupt the maturation of
this brain region, which coordinates and controls endo-
crine systems [5]. This aberrant development could in
turn induce long-term effects on metabolism and other
neuroendocrine systems.
Many growth factors, metabolites, and hormones im-
pact on brain development, with some of their effects
being characteristic of specific brain nuclei or systems;
for example, leptin is implicated in the development of
metabolic circuits [6–8]. Leptin, an adipokine produced
mainly by adipocytes, is involved in postnatal metabolic
control [8–10]. It has also been implicated in hypothal-
amic development, as well as synaptic plasticity, neuro-
genesis, and neuronal and glial survival in diverse brain
areas [6, 7, 10, 11]. In rodents, there is a postnatal leptin
surge beginning around postnatal day (PND) 5 with a
peak between PND9 and PND10 [12]. Some of the long-
term metabolic outcomes in response to changes in neo-
natal nutrition are at least partially due to structural and
functional changes in the hypothalamus that most likely
result from the modifications of this leptin surge [8, 13,
14]. Leptin is also involved in reproductive function [15,
16], but the long-term effects of changes in the neonatal
leptin surge on this system are less well studied.
During the last decade, we have studied maternal
deprivation (MD) as a model of a psychoneuroimmu-
noendocrine disorder [17]. In these studies, we observed
that MD during 24 h starting on PND9 induces long-
term modifications in the endocrine, immune, endocan-
nabinoid, and glutamatergic systems, as well as behav-
ioral modifications, with many of these effects being
sexually dimorphic [17]. During MD, there are import-
ant alterations in neuronal and glial markers and neuro-
trophic factors in the hypothalamus, such as a decrease
in levels of nestin, brain-derived neurotrophic factor,
and glial fibrillary acidic protein, with these modifica-
tions being generally more pronounced in males [18]. At
PND13, 3 days after termination of the MD procedure,
hypothalamic cell turnover is elevated, again with males
being more affected [19]. These observations suggest
that MD induces structural modifications in this brain
area and that these modifications may be sexually di-
morphic. During the 24-h MD protocol, the neonates
experience a rise in serum corticosterone and a decrease
in glucose, insulin, and leptin levels [18]. These changes
are all potentially capable of inducing long-term effects
on brain development [6, 20–23].
Growth and metabolism are affected by MD, with this
experimental protocol resulting in reduced body mass,
energy intake and circulating leptin levels throughout
life [13]; however, these animals have an increased
weight gain and inflammatory response to high-fat diet
intake, as well as a sexually dimorphic response in
changes in insulin sensitivity and metabolic hypothal-
amic neuropeptide expression [13]. Moreover, we have
shown that blockage of the neonatal leptin surge not
only affects long-term metabolism and the hypothalamic
expression of metabolic neuropeptides in a sexually di-
morphic manner [24], but also modulates the expression
of members of the kisspeptin system in peripubertal rats
[25], suggesting a possible effect on pubertal develop-
ment. Hence, MD on PND9 could also affect pubertal
development and reproductive function, possibly due to
the dramatic decline in circulating leptin levels during a
critical period of hypothalamic development.
Thus, the aims of this study were to: (1) delineate
which of the previously described long-term meta-
bolic/neuroendocrine effects of MD result from the
MD-induced decline in circulating leptin levels; (2)
determine if the MD procedure modifies the repro-
ductive axis including the timing of pubertal onset,
expression of gonadotrophins and neuropeptides involved
in reproduction in the adult rat and male sexual behavior;
(3) analyze whether the effects of MD on the reproductive
axis are due to the reduction in circulating leptin levels
that occurs during this procedure; (4) determine if males
and females respond similarly to these experimental ma-
nipulations. To this end, rats subjected to MD and control
rats received daily leptin treatment or vehicle between
PND9 and PND13. Metabolic parameters, pubertal onset,
sexual behavior, and hypothalamic metabolic and repro-
ductive neuropeptide expression were analyzed to deter-
mine if this leptin treatment could protect from or palliate
some of the deleterious effects of MD.
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Methods
Animals
Adult Wistar rats were purchased from Harlan Interfauna
Ibérica S.A. (Barcelona, Spain) and allowed to acclimate
for 2 weeks before mating. For mating, one male was
placed in a cage with two females for 10 days. On the day
of birth (PND0), litters were culled to four male and four
female pups per dam, with no cross-fostering being
employed. In order to reduce the litter effect, three differ-
ent litters were used in all experimental groups and in all
analyses, with a total of 12 rats in each experimental
group. Rats were maintained at a constant temperature
(22 ± 1 °C) and humidity (50 ± 2 %) in a reversed 12-h
light-dark cycle (red light on at 08:00 and white light on at
20:00) and given free access to rat chow (commercial diet
for rodents 2918; Harlan Laboratories, Madison, WI,
USA) and water.
The experimental procedures were approved by the
University Ethical Committee for Animal Experimenta-
tion and complied with the Royal Decree 53/2013 and
with the European Union guidelines for use of experi-
mental animals (2010/63/EU).
Maternal deprivation
A schematic drawing of the experimental design is
shown in Fig. 1. Maternal deprivation was performed as
previously described [26]. Briefly, beginning at 09:00 on
PND9, mothers from the deprived group were removed
and placed in a cage next to the home cage in the same
room and returned to their home cage on PND10.
Mothers of the control litters were left undisturbed.
Leptin treatment
Rats were injected sc with 3 mg/kg body mass (bm) of
rat leptin (National Hormone and Pituitary Program,
Torrance, CA) from PND9 until PND13. The rats re-
ceived one injection per day at 9:00. Control rats re-
ceived the same volume (2.5 ml/kg bm) of vehicle
(saline + 0.1 % BSA). This leptin dose was selected as it
has been previously shown to activate leptin signaling
and modulate neuropeptide expression in the neonatal
animal [27]. Because leptin returns to baseline levels
24 h after injection [28], leptin was administered daily.
Daily injection was performed from the time of separ-
ation from their mother (PND9), until PND13 when the
physiological neonatal leptin surge terminates [12]. After
each injection, the rats were immediately returned to
their mothers. All rats were then left undisturbed from
PND13 until they were weaned at PND22. At weaning,
the rats were separated and placed two rats of the same
sex and experimental group/cage.
This treatment protocol resulted in four different groups
of both males and females: Controls + vehicle: CoVh,
Controls + leptin treatment: CoLeptin, maternal deprived
+ vehicle: MDVh, and maternal deprived + leptin treat-
ment: MDLeptin. Each experimental group consisted of
12 animals from three different litters (4 animals/litter).
Weight, food, pubertal control, and oral glucose tolerance
test (OGTT)
Body mass and food intake were monitored weekly from
weaning (PND22) until 5 days before being killed. Food
intake was measured by placing a known amount of food
in each cage and measuring the remaining amount at
the same time the following week.
Pubertal onset was measured by monitoring vaginal
opening (VO) or balano preputial separation (BPS). Due
to the differences in age of pubertal onset, this monitor-
ing started on PND30 in females and PND35 in males.
On PND60 at 9:00, an OGTT was performed. Glucose
was administered orally (1 g/kg). Glucose levels were
then determined in tail blood 15, 30, 60, and 120 min
later by using a glucometer (Optium Plus, Abbot Dia-
betes Care, Witney Oxon, UK).
Sexual behavioral testing
Female sexual behavior was not analyzed in order to
avoid stress due to estrous cycle monitoring and to avoid
the possibility of pregnancy.
Fig. 1 Experimental design diagram. This diagram indicates the day or days when maternal deprivation, leptin treatment, weaning, control of
pubertal onset, blood sampling, glucose tolerance testing, and behavioral testing were performed. PND postnatal day
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Male sexual behavior was tested at PND84. For this
test, stimulus female rats (300 ± 20 g) that were not a
part of this study were induced to become sexually re-
ceptive by a subcutaneous injection of 50 mg of estradiol
benzoate (Sigma-Aldrich) 48 h before testing, followed
by injection of 500 mg of progesterone (Sigma-Aldrich)
4 h before testing. The experiments, performed during
the central part of the dark period (12:00–16:00), were
carried out in a square arena (60 cm × 60 cm × 45 cm)
with matte-painted metallic floor and Perspex walls
under red illumination provided by two 40 W fluores-
cent lamps. Each male rat was observed alone for 5 min.
An estrous female was then introduced into the center
of the arena and his behavior was recorded. Each test
lasted a maximum of 30 min. If no intromission was dis-
played within the first 15 min, the test was terminated
and the male was considered a “non-copulator”. Video
tape recordings were later replayed and analyzed (in
slow motion when necessary), and the following parame-
ters were measured: (1) mount latency (ML; in seconds)
defined as the time between introduction of the female
rat and the first mount; (2) intromission latency (IL; in
seconds) considered as the time between introduction of
the female rat and the first intromission; (3) mount fre-
quency, which was the number of mounts displayed be-
fore ejaculation; (4) intromission frequency, determined
as the number of intromissions displayed before ejacula-
tion; (5) ejaculation frequency, defined as the number of
ejaculations during the test session; (6) ejaculation la-
tency, which was the time between the first intromission
and ejaculation; (7) total mounts/intromission frequency,
calculated as the total number of mounts/intromission
frequency; (8) inter-copulatory interval (ICI) calculated
from the ejaculation latency/intromission frequency in
each copulatory series; (9) pseudo inter-copulatory inter-
val (pseudo-ICI) for non-ejaculating rats, which repre-
sents the time from the first intromission to the end of
the 30 min session/number of intromissions; (10) copu-
latory rate (the sum of mounts and intromissions di-
vided by the elapsed time (s) from the first mount until
an observed ejaculation); (11) percentage of rats display-
ing copulatory activity; and (12) percentage of rats
achieving ejaculation.
After each trial, animals were placed back into their
home cages with littermates and the arena was thor-
oughly cleansed with water. These animals were submit-
ted to other behavioral tests prior to the sexual test such
as novel object test and elevated plus maze (manuscript
submitted) with an interval of 7 days between each test.
For the statistical analyses, we used between 10 and 11
males and females per experimental group from three
different litters (3–4 animals/litter/experimental group).
All animals were submitted to the behavioral tests, and
only the animals that did not fulfill the test requirements
(two CoVh males, one CoLeptin male, one MDLeptin
male, and two MDLeptin males) were excluded from the
statistical analyses.
Tissue collection
Blood was collected from the tail vein at PND36 in
tubes containing EDTA (0.5 M) and rapidly placed on
ice. On PND90, after a 12-h fast, all rats were killed by
rapid decapitation. The estrous stage of each female
was determined on the day of sacrifice, with 80 % of
the rats found to be in estrus and 20 % in metestrus,
with no difference between groups. Trunk blood was
collected in tubes and rapidly placed on ice and kept
overnight at 4 °C. The blood was centrifuged (1600g for
15 min) and the serum collected and stored at −20 °C
until processed. The brain was rapidly removed and the
hypothalamus was dissected and the pituitary was col-
lected. They were then frozen in liquid nitrogen and
stored at −80 °C until processed.
Leptin enzyme-linked immunosorbent assay (ELISA)
Plasma leptin levels were measured at PND36 by using
B-bridge mouse/rat leptin ELISA kits (Cupertino, CA,
USA) following the manufacturer’s instructions. The
assay sensitivity is 0.5 ng/ml, with an inter-assay vari-
ation of 6.5 % and intra-assay variation of 3.7 %. All
samples were run in duplicate. For this assay, we used 6
males and 5–6 females per experimental group from
three different litters (1–2 randomly selected animals/lit-
ter/experimental group).
Multiplexed magnetic bead immunoassay
Insulin levels were measured in duplicate in serum
collected at PND90 by a multiplexed magnetic bead
immunoassay kit (Millipore Corporation) as previously
described [29]. Briefly, beads conjugated to the appro-
priate antibodies and serum samples (25 μl each) were
incubated overnight at 4 °C with shaking. Wells were
washed three times using a wash buffer and antibody
conjugated to biotin (50 μl) was added. After incubation
for 30 min at room temperature with shaking, beads
were incubated during 30 min with 50 μl streptavidin
conjugated to phycoerythrin. Beads were analyzed in the
Bio-Plex suspension array system 200. Raw data (mean
fluorescence intensity) was analyzed using the Bio-Plex
Manager Software 4.1 (Bio-Rad Laboratories). Leptin
was also measured in this assay. These results have been
previously reported (manuscript submitted).
For this analysis, we used between 5 and 8 males and
females per experimental group from three different lit-
ters (1–3 randomly selected animals/litter/experimental
group).
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Corticosterone and testosterone radioimmunoassay
Corticosterone was measured in serum collected at
PND36 and PND90 using a solid phase I125 radio-
immunoassay (Immunochem Double Antibody Cort;
MP Biomedicals, Illkirch, France). The detection limit
was 7.7 ng/ml and the inter- and intra-assay coefficients
of variation were less than 10 %.
Plasma testosterone levels were measured in serum
collected at PND90 with RIA Coat-a-Count® kits from
Siemens (Los Angeles, USA) following the manufac-
turer’s instructions. The detection level was 4 ng/dl. The
intra- and inter-assay coefficients of variation were 6.0
and 6.4 %, respectively.
Between 5 and 8 males and females per experimental
group from three different litters (1–3 randomly selected
animals/litter/experimental group) were used for these
assays.
Estradiol-17β ELISA
Plasma 17-β estradiol levels were determined in serum
collected at PND90 by using an ELISA from Enzo
(Farmingdale, NY, USA). Absorbance in each well was
measured by using a Tecan Infinite M200 (Grodig,
Austria), and serum concentrations were calculated from
the standard curve. This assay has a sensitivity of
14.0 pg/ml and inter- and intra-assay coefficients of vari-
ation of 8.3 and 2.1 %, respectively.
All samples were run in duplicate and in the same
assay for all hormones. For this assay, between 5 and 6
females per experimental group from three different lit-
ters (1–2 randomly selected animals/litter/experimental
group) were used.
Triglyceride assay
Triglycerides were measured in serum collected at
PND90 by using commercial kits (Randox, Antrim, UK)
according to the manufacturer’s instructions. Serum
samples (in duplicate) were incubated with the commer-
cial solution containing lipoprotein lipase, glycerol kin-
ase, glycerol-3-oxidase, peroxidase, 4-aminophenazone,
and ATP for 5 min at 37 °C under agitation. The result-
ing color was detected at 500 nm in a spectrophotom-
eter and compared to a standard curve.
For this assay, we used between 7 and 8 males and
females per experimental group from three different
litters (2–3 animals/litter/experimental group, randomly
selected).
Quantitative real-time PCR
Total RNA from approximately 50–100 mg of hypothal-
amic tissue, divided into rostral (HTr) and caudal or
medial basal (MBH) areas using the optic chiasm as
reference, was isolated using TRIsure Reagent (Bioline,
London). High-Capacity cDNA Reverse Transcription
kits (BioRad Laboratories, Hercules, CA) were used ac-
cording to the manufacturer’s protocol on a iCycler iQ
PCR Thermal Cycler (BioRad) to transcribe 0.5 μg total
RNA isolated from each tissue.
Aliquots of the resulting complementary deoxyribo-
nucleic acid (cDNA) samples were amplified by PCR
with specific oligonucleotide primer pairs designed to
span intron/exon borders. The sequence of the primer
pairs used were [1] rat Kiss1, forward 5′ GCT GCT
GCT TCT CCT CTG TG 3′ and reverse 5′GCA TAC
CGC GGG CCC TTT T 3′; [2] rat Gpr54, forward 5′
GCC ACA GAT GTC ACT TTC CTT C 3′ and reverse
5′GCC ACA GAT GTC ACT TTC CTT C 3′; [3] rat
RFRP (RFamide-related peptide), forward 5′ AAT CCC
TGC ACT CCC TGG CCT 3′ and reverse 5′AAG GAC
TGG CTG GAG GTT TCC 3′; and [4] rat NPFFR1
(neuropeptide FF receptor 1), forward 5′ AAC CGG
CAC ATG CGC ACT GTC 3′and reverse 5′ GAC ATG
CCC TGC ACC AAG CCG 3′. Amplification of S11,
forward 5′ CAT TCA GAC GGA GCG TGC TTA C 3′
and reverse 5′ TGC ATC TTC ATC TTC GTC AC 3′
served as control for the RT-PCR reactions. Amplifica-
tion of the cDNA template was performed using 1x iQ
Supermix and SYBR green for each detected gene
(Promega, Wisconsin, USA). Predesigned commercial
expression assays were used for the following genes:
neuropeptide Y (NPY; Rn01410145_m1), proopiomela-
nocortin (POMC; Rn00595020), agouti-related peptide
(AgRP; Rn014311703_g1), cocaine- and amphetamine-
regulated transcript (CART; Rn00567382_m1), orexin
(Rn00565995_m1) and the leptin receptor (LepR;
Rn01433250_m1). Results were normalized to Pgk1
(Rn00569117_m1) mRNA levels in all samples.
Total RNA was extracted from each pituitary with
TRIzol® Reagent (Invitrogen). High-Capacity cDNA
Reverse Transcription kits (Applied Biosystems, Foster
City, CA) were used according to the manufacturer’s
protocol on a Peltier thermal Cycler Tetrad2 (BioRad) to
transcribe 2 μg total RNA. Amplification of the cDNA
template was performed with an ABI PRISM 7900HT
sequence detection system (Applied Biosystems) using
TaqMan Universal PCR Master Mix (Applied Biosystems)
and TaqMan Gene Expression Assay kits for each gene
(Applied Biosystems). The pituitary follicle-stimulating
hormone (βFSH; Rn01484594_m1) and luteinizing
hormone (βLH; Rn00563443_g1) were analyzed. Re-
sults were normalized to 18S (Rn01428915_g1) mRNA
levels.
According to manufacturer’s guidelines, the ΔΔCT
method was used for relative quantification. Statistics
were performed using ΔCT values.
Between 5 and 6 males and females per experimental
group from three different litters (1–2 randomly selected
animals/litter/experimental group) were used for these
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assays. Samples that did not meet the standards of purity
and/or integrity were excluded.
Statistical analysis
Normality was checked by Shapiro-Wilks’s test (p > 0.05).
The criterion of normally distributed data were not always
met in some populations under study; thus, when neces-
sary data were transformed by the Neperian logarithm
function, aiming to satisfy the assumption of normality for
ANOVA. To control for a possible litter effect, we per-
formed ANCOVA analyses (including “litter” as a covari-
ate). Body mass gain and food intake were analyzed by
three-way ANCOVA with the factors being sex (males
and females), MD (Co: maternal non-deprived; MD: de-
prived rats) and leptin treatment (Vh: vehicle; Leptin
treatment: Leptin), with repeated measures. Three-way
ANCOVA was used to analyze results when tissue from
males and females were processed simultaneously (hor-
mone assays, OTTG, and PCR), followed by two-way
when appropriate. Two-way ANCOVAs were employed
when males and females were processed separately (pu-
bertal onset, sex hormone assays, and sexual behavior).
Tukey’s test was used for post hoc comparisons. The level
of significance was chosen as p < 0.05. All results are
reported as mean ± SEM. In the figures, only physiolo-
gically relevant comparisons are demonstrated. Although
changes in body mass were analyzed simultaneously in
both sexes, the results are represented in the figures separ-
ately to facilitate interpretation.
Results
Effects of MD and leptin treatment on metabolic
parameters: body mass gain, accumulated food intake,
and OGTT
Body mass varied according to age [F(2.07,729) =
1166.80; p < 0.005], sex [F(1,81) = 923.55; p < 0.005] with
an interaction between age and sex [F(2.07,729) =
969.37; p < 0.005], with females weighing less than males,
and to MD [F(1,81) = 22.36; p < 0.005] with an inter-
action between age × sex ×MD × Lept [(2.07,729) = 4.01;
p < 0.05]. MD rats of both sexes had a lower body mass
than their controls until PND57 (Fig. 2a, b). A signifi-
cant effect of sex [F(1,81) = 265.67; p < 0.005] was found
Fig. 2 Changes in body mass and food intake throughout the study. a, b Mean body mass (BM), c accumulated BM gain, and d accumulated
food intake per rat from the time of weaning until 5 days before being killed. e Glucose tolerance test (area under the curve), in maternal deprivation
(MD) or control (Co) male and female rats treated with leptin (Lept) or vehicle (Vh) from postnatal day (PND) 9 until PND13 (n = 10–12). Body mass
was reduced by MD in both sexes until approximately PND57, while leptin treatment of MD rats returned body mass to control levels.
Males weighed more and ate more than females throughout the study and were less glucose tolerant. a, b Data were analyzed by a
repeated measure three-way ANCOVA: (a) main effect of sex; Tukey’s post hoc test: *** CoLeptin vs. MDLeptin (p < 0.005), @@ MDLeptin
vs. CoVh (p < 0.01) and ### MDVh vs. MDLeptin (p < 0.005). c–e Data were analyzed by three-way ANCOVA: (a) main effect of sex;
(b) main effect of MD. Tukey’s post hoc: **p < 0.01; ***p < 0.005
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on accumulated body mass gain with female rats gaining
less than males (Fig. 2c).
There was an interaction between sex ×MD × leptin
[F(1,81) = 7.96; p < 0.01] on the accumulated energy in-
take. Females ate less than males in all corresponding
groups (Fig. 2d). Leptin-treated MD males consumed
less energy than CoVh males.
Significant effects of sex [F(1,81) = 45.81; p < 0.005]
and neonatal leptin treatment [F(1,81) = 8.99; p < 0.01]
were found on baseline glucose levels (males: CoVh
81.0 ± 2.8; CoLeptin 101.3 ± 3.8; MDVh 88.2 ± 2.2;
MDLeptin 96.4 ± 1.8; females: CoVh 76.2 ± 2.9; CoLeptin
81.4 ± 3.3; MDVh 73.2 ± 3.8; MDLeptin 87.8 ± 5.3 mg/dl),
with males having higher levels than in females and leptin
treatment increasing baseline glucose levels. During the
OGTT, there were significant effects due to sex [F(1,81) =
33.55; p < 0.005] and MD [F(1,81) = 4.33; p < 0.05]. Female
rats were more glucose tolerant than males and MD in-
creased glucose tolerance in both sexes (Fig. 2e), with no
effect of leptin treatment.
Long-term effect of MD and neonatal leptin treatment on
circulating hormone and triglyceride levels
At PND36, a main effect of sex [F(1,37) = 9.83; p < 0.005]
was found on circulating leptin levels. Females had lower
leptin levels (Fig. 3a) than males. An interaction between
sex and MD was also found [F(1,37) = 4.32; p < 0.05]
and two-way ANCOVA (split by sex) revealed a de-
crease in leptin levels in males due to MD [F(1,19) = 6.18;
p < 0.05].
To determine if corticosterone levels remained ele-
vated as seen during the MD protocol [17], serum
levels were measured at PND36. A main effect of sex
[F(1,32) = 12.51; p < 0.005] was found with females
having higher corticosterone levels. An interaction be-
tween MD and leptin treatment was also found
[F(1,32) = 5.05; p < 0.05], and two-way ANCOVA (split
by leptin treatment) revealed a decrease in corticosterone
levels in MDVh males [F(1,16) = 11.14; p < 0.005] and fe-
males [F(1,15) = 4.84; p < 0.05] (Fig. 3b).
At PND90, a significant effect of sex was found on cir-
culating corticosterone [F(1,55) = 13.88; p < 0.005] levels.
Females had higher corticosterone (Fig. 3c) levels
than males regardless of treatment. An interaction be-
tween sex and leptin treatment was found [F(1,55) = 7.25;
p < 0.01], with MDLeptin females having lower levels than
CoVh females.
At PND90, there was an interaction between MD and
leptin treatment on insulin levels in males [F(1,22) =
36.03; p < 0.005], with both CoLeptin males and MDVh
males having higher levels than in CoVh males. Leptin
treatment normalized the increase observed in MD
males (Fig. 3d).
A main effect of leptin treatment [F(1,52) = 7.98; p < 0.01]
was found on circulating triglyceride levels, with an
interaction between sex, MD, and leptin treatment
[F(1,52) = 7.03; p < 0.05]. Two-way ANCOVA (split by
sex) revealed an effect of leptin treatment in males
[F(1,25) = 14.34; p < 0.005] and an interaction between
MD and leptin treatment in females [F(1,26) = 9.93;
p < 0.005]. As shown in Fig. 3e, triglycerides levels tended
to increase in MDVh males and leptin treatment counter-
act this effect (Tukey’s post hoc, p < 0.05), while females
MDVh showed lower levels than in the CoVh group
(Tukey’s post hoc, p < 0.05).
As we have previously found MD to modify sex steroid
levels in adult males [19, 30], we analyzed sex steroid
levels at PND90 to determine the effect of leptin treat-
ment. There was an interaction between MD and leptin
treatment on estradiol levels in PND90 females [F(1,16)
= 13.21; p < 0.005], with MDVh females having lower
levels than in CoVh females. This was normalized in
MDLeptin females (Fig. 3f ).
In males, there was an effect of leptin treatment on
testosterone levels [F(1,22) = 6.84; p < 0.05] at PND90
with higher levels in MD males than the rest of the ex-
perimental groups (Fig. 3g).
Hypothalamic mRNA levels of genes related to metabolic
control
Although we previously found no effect of MD on
hypothalamic expression of neuropeptides involved in
food intake in adult rats [13, 19], changes in the ac-
tions of neonatal leptin can affect these parameters
[8, 25, 28]. As previously reported [13, 19], we found
no effect of MD on NPY (Fig. 4a) or AgRP (Fig. 4b)
mRNA levels in either sex. There was also no effect
of neonatal leptin treatment. However, females had lower
AgRP mRNA levels compared to males [F(1,36) = 19.80;
p < 0.005].
There was an interaction between MD and leptin
treatment on both POMC [F(1,37) = 6.83; p < 0.05] and
CART [F(1,38) = 7.47; p < 0.01] mRNA levels. In males,
POMC mRNA levels were increased by MD (Fig. 4c).
Leptin increased CART mRNA levels in control males,
but not in MD males (Fig. 4d). Although there was no
difference in controls, leptin-treated control males had
higher levels of CART mRNA than in leptin-treated
control females.
There was an interaction between MD and leptin
treatment [F(1,34) = 9.53; p < 0.005] on orexin mRNA
levels in the MBH. Leptin treatment increased orexin
mRNA levels in control males and females (Fig. 4e).
There was no effect of MD on LepR mRNA levels, but
leptin treatment increased them in control males
[F(1,35) = 7.90; p < 0.01] (Fig. 4f ).
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Hypothalamic mRNA levels of genes related to
reproduction
Females had significantly higher Kiss1 mRNA levels in
the HTr [F(1,43) = 88.38; p < 0.005] and in the MBH
[F(1,42) = 28.49; p < 0.005] compared to males. However,
no effects of leptin treatment or MD were found. There
were no significant effects on the mRNA levels of any
of the other factors or receptors involved in the neuro-
endocrine control of reproduction, including Npff1r,
Gpr54, and Rfrp, in either hypothalamic area (Table 1).
Pituitary gonadotrophin mRNA levels
There was no effect of MD or neonatal leptin treatment
on βFSH or βLH mRNA levels (Table 2). However,
females had lower levels of βFSH mRNA in the pituitary
than males [F(1,33) = 77.74; p < 0.005].
Pubertal onset
There was no effect of MD on VO (Fig. 5a). However,
neonatal leptin treatment delayed VO [F(1,39) = 6.23;
Fig. 3 Serum levels of leptin (a) and corticosterone at postnatal day (=ND)36 (b) and of corticosterone (c), insulin (d), 17β-estradiol (e),
and testosterone (f), at PND90 in maternal deprivation (MD) or control (Co) male and female rats treated with leptin (Lept) or vehicle (Vh) from PND9 until
PND13 (n= 7–8). In males, MD decreased leptin and increased insulin and triglyceride levels, with leptin treatment returning insulin and triglycerides to
control levels. In contrast in females, MD decreased triglyceride and estradiol levels, which were also normalized by leptin treatment. a Main effect of sex
(three-way ANCOVA). b Main effect of MD (two-way ANCOVA). Tukey’s post hoc test:*p< 0.05; **p < 0.01; ***p< 0.005
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p < 0.05] regardless of whether the females had been
exposed to MD or not (Fig. 5a).
There was an interaction between MD and leptin
treatment on BPS [F(1,41) = 23.92; p < 0.005]. MDVh
males and CoLeptin males showed anticipated pubertal
onset compared with CoVh males; however, leptin treat-
ment of MD males normalized the appearance of exter-
nal signs of pubertal onset (Fig. 5b).
Sexual behavior
Although leptin treatment tended to increase mount
latency, this effect was not significant (Fig. 6a) and no
effect was found on intromission latency (Fig. 6b). An
interaction between MD and leptin treatment was found
on ejaculation latency [F(1,34) = 14.41; p < 0.005] with
neonatal leptin treatment decreasing ejaculation latency
in control males but not in MD males. CoLeptin males
Fig. 4 Analysis of hypothalamic neuropeptide mRNA levels. Expression levels in the medial basal hypothalamus of the mRNAs encoding NPY (a),
AgRP (b), POMC (c), CART (d), orexin (e), and leptin receptor (LepR) (f) in maternal deprivation (MD) or control (Co) male and female rats treated
with leptin (Lept) or vehicle (Vh) from postnatal day (PND) 9 until PND13 (n = 5–6). In males, MD increased POMC mRNA levels, but leptin
treatment did not normalize this effect. In contrast, leptin treatment of control males increased CART, orexin, and LepR mRNA levels. In females,
there was no effect of MD on the expression of these neuropeptides and leptin treatment of control females only increased orexin expression.
Three-way ANCOVA: (a) main effect of sex. Tukey’s post hoc test: *p < 0.05; **p < 0.01; ***p < 0.005
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had a lower ejaculation latency than MDLeptin males
(Fig. 6c).
Neonatal leptin treatment tended to decrease mount
frequency [F(1,35) = 4.08; p = 0.05; Fig. 6d] and to increase
mount/intromission frequency [F(1,35) = 4.88; p < 0.05] in
MD males (Fig. 6g). There was an interaction between
MD and leptin treatment [F(1,35) = 6.22; p < 0.05] with
leptin increasing ejaculation frequency in controls
[F(1,21) = 7.16; p < 0.05] and decreasing it in MD rats
[F(1,19) = 7.92; p < 0.05; Fig. 6f]. This resulted in CoLeptin
males having a significantly higher ejaculation frequency
than MDLeptin males. There was no effect of either leptin
treatment or MD on intromission frequency (Fig. 6e).
MD tended to decrease pseudo-ICI values [F(1,10) = 4.97;
p = 0.05] with MD males having lower values than Co
males (Fig. 6h). No effect of MD or leptin treatment
was found on ICI (Fig. 6i). There was a significant inter-
action between MD and leptin treatment on copulatory
rate [F(1,33) = 14.89; p < 0.005] with MDLeptin males
having a lower rate than CoLeptin males (Fig. 6j).
Chi-squared analysis showed a significant decrease in
the percentage of rats achieving ejaculation in the
MDLeptin group (χ1 = 6.60, p < 0.05; Fig. 6l), with no
effect on the percentage of rats displaying copulatory
activity (Fig. 6k).
Discussion
We previously reported that MD during 24 h at PND9–
10 decreases adult body mass, energy intake, circulating
leptin levels and increases the gain in body mass in re-
sponse to a high-fat diet [13]. We speculated that at the
least part of these metabolic effects were due to the dra-
matic decline in serum leptin levels during the separ-
ation period of MD [18], as modifications in neonatal
leptin levels affect adult metabolism [28, 31–33]. Here,
we found that some of the MD-induced modifications,
including the increase in serum insulin and triglyceride
levels and advanced external signs of pubertal onset in
male rats and the decrease in serum triglyceride and es-
tradiol levels in females, were reversed by neonatal leptin
treatment, suggesting that part of the long-term effects
of MD are mediated through changes in leptin levels.
However, some effects, such as decreased body mass
gain and food intake, were induced by leptin treatment,
indicating a more complex interaction of these early
events. We also found that MD did not result in the
same metabolic modifications that we previously re-
ported, such as significantly decreased body mass gain
Table 1 mRNA levels of puberty-related genes in rostral (HTr) and medial basal hypothalamus (MBH)
Sex CoVh CoLept MDVh MDLept
Kiss1 HTr M 100 ± 8.0 95.6 ± 16.0 109.7 ± 9.0 114.4 ± 25.0
F 438.4 ± 146.2a 467.1 ± 109.8a 506.8 ± 84.3a 319.2 ± 45.6a
Kiss1 MBH M 100 ± 8.0 126.3 ± 12.9 116.4 ± 8.7 128.0 ± 19.5
F 192.0 ± 22.2a 185.5 ± 33.6a 172.1 ± 18.8a 215.6 ± 31.5a
Gpar54 HTr M 100 ± 9.2 95.4 ± 6.6 102.5 ± 6.3 92.2 ± 12.3
F 123.0 ± 12.2 100.8 ± 6.3 100.8 ± 6.1 94.8 ± 4.9
Gpar54 MBH M 100 ± 8.0 99.4 ± 3.9 103.9 ± 5.0 111.9 ± 9.6
F 119.9 ± 4.1 104.0 ± 5.5 112.6 ± 16.0 104.0 ± 7.3
Rfrp HTr M 100 ± 43.6 17.0 ± 3.4 31.7 ± 6.4 39.8 ± 15.8
F 49.3 ± 11.4 39.0 ± 12.3 88.6 ± 26.1 90.8 ± 38.7
Rfrp MBH M 100 ± 12.9 107.8 ± 13.8 95.1 ± 10.8 117.2 ± 13.7
F 104.9 ± 7.0 110.5 ± 18.6 112.0 ± 11.5 109.9 ± 6.0
Nprffr1 HTr M 100 ± 8.1 110.0 ± 5.4 100.1 ± 4.0 106.7 ± 8.9
F 107.1 ± 11.2 119.7 ± 4.7 98.3 ± 5.6 94.0 ± 12.1
Nprffr1 MBH M 100 ± 12.8 129.2 ± 7.9 110.6 ± 8.2 115.9 ± 7.5
F 107.4 ± 5.1 116.1 ± 10.7 100 ± 5.8 108.6 ± 15.4
Data are expressed as mean ± SEM and normalized to control (Co) values. Co and maternal deprivation (MD) male (M) and female (F) rats with leptin treatment
(Lept) or vehicle (Vh) from postnatal day (PND) 9 to PND13. n = 5–6 per experimental group
aMain effect of sex; three-way ANOVA
Table 2 Gonadotropin mRNA levels in the pituitary
Sex CoVh CoLept MDVh MDLept
βFSH M 100 ± 35.2 47.5 ± 11.7 67.7 ± 9.1 210.9 ± 74.0
F 13.4 ± 4.9a 11.4 ± 5.0a 13.0 ± 6.7a 4.7 ± 0.8a
βLH M 100 ± 34.2 82.2 ± 20.0 76.3 ± 8.0 170.8 ± 70.2
F 86.7 ± 41.2 138.2 ± 50.4 69.4 ± 13.8 80.7 ± 9.2
Data are expressed as mean ± SEM and normalized to control (Co) values.
Control and maternal deprivation (MD) male (M) and female (F) rats with
leptin treatment (Lept) or vehicle (Vh) from postnatal day (PND) 9 to PND13.
n = 5–6 per experimental group
aMain effect of sex; three-way ANOVA
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Fig. 5 Effect of neonatal maternal deprivation and leptin treatment on pubertal onset. Age of pubertal onset assessed by vaginal opening (VO) in
females (a) and balano-prepurcial separation (BPS) in males (b) in maternal deprivation (MD) or control (Co) rats treated with leptin (Lept)
or vehicle (Vh) from postnatal day (PND) 9 until PND13 (n = 10–12). The animals were monitored between days 30 and 38 (females) or
days 35 and 47 (males) for VO or BPS, respectively. In females, neonatal leptin treatment delayed the mean age of VO in both control
and MD rats, with no effect of MD alone. In males, external pubertal signs were advanced with both MD and leptin treatment, with the
combination of these factors normalizing pubertal onset. For the presentation of data, cumulative percentage data of VO/BPS are shown
beside the mean age of VO/BPS. Two-way ANCOVA: (b) main effect of leptin treatment. Tukey’s post hoc: ***p < 0.005; *p < 0.05
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and circulating leptin levels in adulthood. These differ-
ences could possibly be derived from the daily handling of
the pups in order to inject the control vehicle treatment.
Body mass and food intake
Body mass was significantly decreased by MD until ap-
proximately PND57, which is in agreement with some of
our previous studies where this decrease was found in
adolescence and early adulthood, whereas in other stud-
ies, the decrease in body mass was found to persist into
later adult life [13, 30, 34]. Neonatal leptin treatment
further decreased body mass in MD rats, but there was
no significant effect on the overall change in body mass
during the study. In contrast, neonatal leptin treatment
tended to increase adult body mass in control males and
this was associated with a trend towards increased en-
ergy intake. This is in agreement with Toste et al. [35]
where both body mass and food intake were increased in
response to neonatal leptin treatment. However, other
studies report no change in body mass [36–38]. These
discrepancies may be due to the dose and timing of the
leptin treatment or to other factors during development
that can influence the response to leptin. Indeed, MD
modified the response to neonatal leptin treatment in
males as in these rats neonatal leptin treatment reduced
weight gain and food intake. In control females, no effect
of neonatal leptin treatment was observed on body mass
or food intake and this is in agreement with a previous
study Erkonen et al [37]. Moreover, in females, the
response to neonatal leptin treatment was not modified
by MD indicating that numerous factors, including sex,
determine the long-term effects of changes in neonatal
leptin levels on body mass and energy intake. Indeed, we
have previously shown that neonatal leptin treatment
decreases food intake in male rats, but this is a delayed
effect [28]; thus, it is plausible that a change in food in-
take would be observed at older ages, at least in control
males.
Fig. 6 Sexual behavior in male rats. a Mount latency, b intromission latency, c ejaculation latency, d mount frequency, e intromission frequency, f
ejaculation frequency, g mount/intromission frequency, h pseudo-ICI (pseudo intercopulatory interval for non-ejaculating rats), i ICI (inter-copulatory
interval: ejaculation latency/intromission frequency in each copulatory series), j copulatory rate (the sum of mounts and intromissions divided
by the elapsed time (s) from the first mount until an observed ejaculation), k percentage of rats displaying copulatory activity, and l percent-
age of rats achieving ejaculation, of maternal deprivation (MD) or control (Co) male and female rats treated with leptin (Lept) or vehicle (Vh)
from postnatal day (PND) 9 until PND13 (n = 10–12). Ejaculation frequency was increased by leptin in control rats, but decreased by leptin in
MD rats, with the inverse effect seen on ejaculation latency. Two-way ANCOVA: (b) main effect of MD. Tukey’s post hoc: *p < 0.05
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It is possible that body composition is affected by MD
and/or the leptin treatment employed here and that this
is not reflected in a change in body mass. Further studies
are necessary to determine whether fat mass, as well as
its distribution, is affected by MD and if this is due to
the decline in circulating leptin levels induced by this
experimental manipulation.
Circulating hormone levels and glycemia
Here, we found males to have higher circulating leptin
levels than females at PND36, and this was also found
when they reached adulthood [39]. This is in accordance
with the previous studies showing a sex difference in
leptin levels [13, 19, 40], while here, this sex difference
was observed even during the peripubertal period. In
males, MD decreased leptin levels at PND36, but in
adulthood, there was no effect of MD in either sex [39].
This is in contrast to our previous studies where MD
was found to decrease serum leptin levels even in adult-
hood [18, 30, 34]. The stress of saline injection is re-
ported to affect leptin levels [41], and this could mask
the effect of MD possibly by even modulating circulating
leptin levels in the vehicle-treated rats. Neonatal leptin
treatment is reported to increase or have no effect on
circulating leptin levels in later life [28, 37, 41]. More-
over, blocking the neonatal leptin surge was found to
have no effect on body mass or leptin levels during the
peripubertal period [42], but was found to decrease adult
body mass and leptin levels [28]. Thus, as with body
mass, the long-term effects on circulating leptin levels
most likely depend on how and when the neonatal leptin
surge is manipulated, as well as other neonatal condi-
tions such as stress.
In both MD male and female rats, the AUC during the
OGTT was decreased, with no effect of leptin treatment.
During the process of MD, glycemia is decreased [18]
and whether this underlies the long-term effect on glu-
cose metabolism deserves to be analyzed. There was no
long-term effect of MD on fasting glycemia, but fasting
insulin levels were increased in MD males, which might
suggest a degree of insulin insensitivity. This is in con-
trast to our previous studies [13, 18], again suggesting
that handling of MD rats during vehicle injections could
affect some outcomes of the MD procedure. In control
males treated with leptin, insulin levels were increased,
which is in concordance with Passos et al. [43] who re-
ported that young rats treated with leptin during early
postnatal life become hyperinsulinemic. However, the
combination of MD and leptin treatment returned fast-
ing insulin levels to that of controls.
We have previously shown that in females, MD re-
duces corticosterone levels in adolescence [26, 44]. Here,
we found corticosterone levels to be reduced by MD at
PND36 in both males and females, with leptin treatment
normalizing this effect. However, at PND90 cortico-
sterone levels were unaffected by MD or leptin treat-
ment, although they tended to be reduced by MD in
females with leptin treatment having no effect at this
age. Thus, the effects of MD and leptin on circulating
corticosterone levels appear to be both age and sex
dependent. Moreover, at both ages, circulating cortico-
sterone levels were higher in females compared to males,
as previously reported [18, 45].
Hypothalamic neuropeptides
Males that were exposed to MD appear to be more sus-
ceptible to the effect of neonatal leptin on food intake,
with a reduction in accumulated energy intake, and this
reduction could be related to the increase in hypothal-
amic mRNA levels of the anorexigenic neuropeptide
POMC. However, increased POMC mRNA levels were
also found in leptin-treated controls and MD vehicle-
treated rats, where food intake and weight gain were not
reduced. In addition, orexin levels were increased in
MDLeptin males, which would be inclined to increase
food intake. The mRNA levels of this orexigenic neuro-
peptide were increased in leptin-treated controls of both
sexes, although, food intake was not affected. Thus, the
changes in the mRNA levels of metabolic neuropeptides
did not correlate with modifications in food intake or
weight gain. Further studies are necessary to determine
how MD and early leptin treatment modify peptide levels
and secretion of these neuropeptides, including the synap-
tic organization of these metabolic circuits. The increase
in POMC mRNA levels in MD males is discordant with
previous results where we found no effect of MD on hypo-
thalamic mRNA levels of POMC, CART, NPY, or AgRP at
different post-natal ages [13, 18].
Appearance of external signs of pubertal onset
Metabolic modifications during early life, especially in-
creased weight gain, are suggested to impact on pubertal
development with changes in leptin levels possibly being
involved in this phenomenon [46–49]. Here, we found
that both neonatal leptin treatment and MD advanced
the appearance of the external signs of puberty in con-
trol male rats. In contrast, pubertal onset was delayed by
leptin treatment in both control and MD females, with
no effect of MD alone.
Leptin is considered to be a permissive factor for pu-
berty [50], and increased fat mass and leptin levels are
thought to advance pubertal onset [51]. However, this
early increase in leptin levels delayed pubertal onset in
females. It is possible that the age at which the subject is
exposed to increased leptin levels determines how pu-
bertal development is affected. Although hypothalamic
expression of members of the kisspeptin system was
unaffected, the delay in pubertal onset could be due to
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modifications in this system that do not involve changes
in mRNA levels, such as synaptic connectivity or secre-
tion patterns. Likewise, although there was no effect of
either MD or leptin treatment on pituitary βLH or βFSH
mRNA levels, the pattern of gonadotropin release could
be affected and this could in turn affect the activation of
the reproductive axis. In males, there was an increase in
hypothalamic CART mRNA levels. This neuropeptide is
involved not only in metabolism, but also in other
physiological functions such as stress or reproduction, as
CART can facilitate leptin’s action on GnRH neurons to
influence pubertal onset [52]. However, it should be taken
into consideration that the expression levels of neuropep-
tides and gonadotropins were measured in adult animals,
and this may not reflect on what occurs during the puber-
tal transition. Further studies are necessary to determine
what occurs at this specific time-point.
Sex steroids and sexual behavior
Early environmental stresses, such as neonatal handling
or perinatal maternal food restriction, can have long-
term consequences on the reproductive axis and sexual
behavior in both males and females [53–57]. We previ-
ously reported that circulating testosterone levels are
decreased by MD [30], while here, this decline did not
reach significance. Neonatal leptin treatment increased
testosterone levels in adulthood, but only in MD males.
Thus, there was an interaction between MD and leptin
treatment with the combination of these treatments
resulting in increased circulating testosterone levels.
Leptin regulation of normal male reproduction in-
cludes both central and testicular actions [58, 59], but
no effect of either MD or leptin treatment was found on
the expression of gonadotropins or neuropeptides in-
volved in reproduction. As stated above, it is possible
that the neuronal connectivity and/or hormonal pulsati-
lity of this system are modified, with subsequent effects
on physiological functions. Leptin also has a direct in-
hibitory action on testicular steroidogenesis [59, 60],
which has been proposed as the link between decreased
testosterone secretion and hyperleptinemia in obese
men [59, 61]; thus, neonatal leptin treatment could
possibly have a direct effect on testicular development.
Indeed, we have recently shown that blockage of the
neonatal leptin surge increased testicular volume in peri-
natal males [42]. The results reported here suggest that
there is an interaction between early neonatal stress,
such as MD, and changes in leptin levels on serum
testosterone concentrations.
We analyzed whether the changes in testosterone
levels were associated with modifications in sexual be-
havior. To date, there is no information in the literature
as to how MD or neonatal leptin levels affect sexual be-
havior. In rat models of sexual behavior, mount latency,
mount frequency, and intromission latency can be consid-
ered as measures of sexual desire and motivation, while
intromission and ejaculation latency are measures of per-
formance (consummatory behavior) [62]. Leptin treatment
of control males appears to affect sexual performance in
control males, decreasing ejaculation latency, but not in
MD males. However, although leptin treatment of MD
males increased serum testosterone levels, it decreased
sexual motivation. The only apparent effect of MD alone
on sexual behavior was a decrease in pseudo-ICI, which
might be interpreted as an increase in sexual desire and
motivation. Libido is under psychosomatic, neurogenic,
vascular, and hormonal control (Waller et al. 1985).
Current hypotheses suggest that dopaminergic activity is
associated with sexual desire and erectile response, while
central serotonergic activity is inhibitory to the erectile
and orgasmic function [63]. In line with this, in previous
studies, we found an increase in serotonin levels due to
MD [64]. Thus, the MD-related increase of pseudo-ICI
might be more associated with an increase of sexual desire
rather than consummatory behavior. However, neonatal
leptin treatment might function to increase sexual per-
formance, as shown by its effects on ejaculation latency
and mount/intromission frequency.
In females, estradiol levels were decreased by MD and
returned to control levels with leptin treatment. Leptin
plays an important role in female reproduction, with
effects on gonadal function, pregnancy, and implantation
[65–67], with female fertility being dependent on adequate
metabolic status [68, 69]. Deregulation of leptin levels
might be responsible for some reproductive problems
such as infertility [70]; however, little is known regard-
ing long-term effects of early stress and modifications
in leptin levels on female reproduction. It is possible
that the dramatic reduction in leptin produced by MD
is interpreted as a signal that the nutritional status of
the immediate environment is not conducive to future
reproduction. The possible involvement of leptin in this
phenomenon is suggested by the fact that neonatal leptin
treatment normalized adult estradiol levels. Whether MD
affects female fertility remains to be determined.
Sex differences in the response to MD and neonatal
leptin treatment
Males and females differ in their response to MD and
neonatal leptin treatment, as well as the interaction be-
tween these two factors. As the development of the male
and female brain differ temporally [71], the response to
these experimental manipulations might be expected to
differ. Indeed, the modifications in cell turnover and
neurotrophic factors during MD are different between
males and females [18], suggesting a differential re-
sponse to this stress. Moreover, the neuroendocrine sys-
tems studied here are sexually dimorphic in normal
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adult animals [72]; hence, one might expect the long-
term responses to this early stress to also differ. In
general, females appear to be less affected in the studies
presented here, which could indicate a greater resilience
to factors that affect growth and reproduction.
Summary and critical discussion
In summary, the results reported here further emphasize
the importance of the postnatal leptin surge in brain de-
velopment and indicate that the long term-consequences
depend upon the manner in which this disruption oc-
curs, as well as the sex of the animal. Indeed, some of
the consequences of MD appear to be due, at least in
part, to modifications in the leptin surge as leptin treat-
ment of MD rats normalized some parameters. However,
in some instances, MD and leptin treatment had the
same effect or even additive effects. One caveat that
must be considered is the regimen of leptin treatment.
The daily injection results in a supraphysiological peak
of serum leptin levels by 1 h after treatment. These
levels remain elevated at 3 h and began to decline at 6 h
after injection, returning to baseline levels by 24 h [28].
This leptin regimen induced long-term effects even in
control rats. However, the response to this leptin treat-
ment varied depending on the baseline circumstances of
the animal (MD or control) or whether they were male
or female.
Another caveat that should be taken into consideration
when analyzing the data presented here is that we have
used more than one rat from each individual litter. Al-
though the statistical analyses indicated that there was
no litter effect in these studies and litters were equalized
in the number of pups and balanced in the number of
males and females, the response of offspring to changes
in leptin levels during development can be affected by
maternal/litter characteristics [38].
The experimental procedure of maternal deprivation
not only modifies circulating leptin levels, but it also
affects the levels of other hormones, such as cortico-
sterone and insulin, and affects maternal behavior once
the pup is returned to its mother [34]. This increase in
maternal care may buffer or compensate the negative
consequences of the extended mother/pup separations
[73]. Moreover, the changes in diverse factors most likely
interact to induce some of the diverse long-term out-
comes of MD. Indeed, the experimental procedure of
MD has been extensively used as a model of neuro-
psychiatric symptoms, but it also has been shown to
affect the immune and endocrine systems [74]. Similar
situations may also occur in human development. For
example, in situations of child neglect, more than one
factor is affected (e.g., stress, food intake, and possibly
temperature) and there are long-term effects on numer-
ous systems [75, 76]. However, as changes in neonatal
leptin levels are known to affect the development of
some endocrine systems [8], here, we asked whether the
MD-induced effects on metabolism and reproduction
could be explained, at least in part, by the resulting
modifications in leptin levels. Indeed, although we are
unable to separate the long-term effects of each individ-
ual change that occurs during MD or their interactions,
our results indicate that the decrease in serum leptin
levels induced by MD is involved in some of the
observed effects on neuroendocrine systems.
Conclusions
The results reported here clearly demonstrate that the
early neonatal environment has important long-term
influences on neuroendocrine systems, including puberty
and sexual behavior, and that these outcomes are com-
plex depending on numerous interacting factors includ-
ing the sex of the animal. Changes in serum leptin levels
during maternal deprivation appear to be involved in at
least some of the resulting long-term metabolic and
reproductive effects of this early stress. Moreover, our
results further emphasize the importance of appropriate
control groups during early manipulations due to the
vulnerability of the developing systems even to vehicle
treatments.
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